Eranostix

Eranostix aims to introduce existent molecular diagnostics and therapeutics technologies from countries such as the US, UK and so on, in emerging markets with mass populations to solve issues of accessibility and affordability of healthcare - and using such an infrastructure to curate one of the most extensive, anonymised clinical databases to establish multiomics-driven clnical R&D in these emerging markets. We aim to achieve this through mass testing tactics, making use of point-of-care testing technologies such as rapid tests, lateral flow tests, as well as more traditional tests but done on more compactified analysers - all time-tested solutions in deployment in more developed countries. The deployment of existent tech in the immediate future would help solve the most pressing healthcare accessibility issues in Bangladesh and other emerging markets like it. However, in order to ensure such access is maintained by the target population(s), the extensive use of a fully anonymised clinical database - procured through our mass testing efforts - is also essential for multiomics-driven R&D on novel tests and drugs to continue addressing the continually evolving climate of healthcare. Eranostix is set to begin operations in Bangladesh, where we have an extensive network in the healthcare space - be it within governmental institutions, private hospitals, or directly with clinicians and physicians - before continuing our expansion to markets abroad. We are open to discussions regarding any interests in business partnerships or investments; please reach out to muhtasimmannan@gmail.com to discuss further (website still under development)